COST-EFFECTIVENESS ANALYSIS OF APIXABAN COMPARED TO OTHER DOACS FOR PREVENTION OF STROKE IN AUSTRIAN ATRIAL FIBRILLATION PATIENTS

被引：0
|
作者：
Walter, E. [1 ]
Voit, M. [1 ]
Eichhober, G. [1 ]
机构：
[1] Inst Pharmaecon Res, Vienna, Austria
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV42
引用
收藏
页码：S548 / S548
页数：1
相关论文
共 50 条
  • [21] Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan
    Liu, Chieh-Yu
    Chen, Hui-Chun
    CLINICAL DRUG INVESTIGATION, 2017, 37 (03) : 285 - 293
  • [22] AN UPDATED COST-EFFECTIVENESS PAIRWISE ANALYSIS OF APIXABAN AND WARFARIN FOR STROKE PREVENTION IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION IN FRANCE
    Lanitis, T.
    Bregman, B.
    Maunoury, F.
    Prawitz, T.
    Gaudin, A.
    Cotte, F.
    VALUE IN HEALTH, 2018, 21 : S105 - S105
  • [23] COST-EFFECTIVENESS OF RIVAROXABAN COMPARED WITH WARFARIN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION
    Kapur, A. K.
    Chatzitheofilou, I
    Schang, L. K.
    VALUE IN HEALTH, 2012, 15 (04) : A122 - A122
  • [24] Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation
    Freeman, James V.
    Zhu, Ruo P.
    Owens, Douglas K.
    Garber, Alan M.
    Hutton, David W.
    Go, Alan S.
    Wang, Paul J.
    Turakhia, Mintu P.
    ANNALS OF INTERNAL MEDICINE, 2011, 154 (01) : 1 - U129
  • [25] Cost-Effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation
    Lee, Soyon
    Anglade, Moise W.
    Dan Pham
    Pisacane, Robyn
    Kluger, Jeffrey
    Coleman, Craig I.
    AMERICAN JOURNAL OF CARDIOLOGY, 2012, 110 (06): : 845 - 851
  • [26] Cost-effectiveness of Dabigatran and Rivaroxaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation
    Ye Wang
    Feng Xie
    Ming Chai Kong
    Lai Heng Lee
    Heng Joo Ng
    Yu Ko
    Cardiovascular Drugs and Therapy, 2014, 28 : 575 - 585
  • [27] Cost-effectiveness of Dabigatran and Rivaroxaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation
    Wang, Ye
    Xie, Feng
    Kong, Ming Chai
    Lee, Lai Heng
    Ng, Heng Joo
    Ko, Yu
    CARDIOVASCULAR DRUGS AND THERAPY, 2014, 28 (06) : 575 - 585
  • [28] Cost-effectiveness of apixaban versus other oral anticoagulants and aspirin for stroke prevention in atrial fibrillation in indian subcontinent
    Kulkarni, N.
    Taur, S.
    Tichy, E.
    Kongnakorn, T.
    Sharma, R.
    EUROPEAN HEART JOURNAL, 2022, 43
  • [29] COST-EFFECTIVENESS OF APIXABAN VERSUS OTHER NEW ORAL ANTICOAGULANTS AND WARFARIN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION IN VENEZUELA
    Fernandez Avila, Y.
    Garcia, K. C.
    Garrido Lecca, S.
    Donato, B. M.
    Juarez-Garcia, A.
    VALUE IN HEALTH, 2015, 18 (07) : A829 - A829
  • [30] Cost-effectiveness of apixaban against current standard of care (SoC) for stroke prevention in atrial fibrillation patients
    Dorian, P.
    Kongnakorn, T.
    Phatak, H.
    Rublee, D.
    Kuznik, A.
    Lanitis, T.
    Liu, L.
    Iloeje, U.
    Lip, G. Y. H.
    EUROPEAN HEART JOURNAL, 2012, 33 : 969 - 969
12345